Last update 28 May 2025

Temsirolimus

Overview

Basic Info

Drug Type
Non-degrading molecular glue
Synonyms
Temsirolimus (JAN/USAN/INN), CCI-779, NSC-683864
+ [5]
Action
inhibitors
Mechanism
FKBP12 (FK506-binding protein 1A ligand), mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors)
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (30 May 2007),
RegulationOrphan Drug (United States), Orphan Drug (South Korea)
Login to view timeline

Structure/Sequence

Molecular FormulaC56H87NO16
InChIKeyCBPNZQVSJQDFBE-UHFFFAOYSA-N
CAS Registry162635-04-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Advanced Renal Cell Carcinoma
South Korea
24 Oct 2008
Mantle-Cell Lymphoma
European Union
19 Nov 2007
Mantle-Cell Lymphoma
Iceland
19 Nov 2007
Mantle-Cell Lymphoma
Liechtenstein
19 Nov 2007
Mantle-Cell Lymphoma
Norway
19 Nov 2007
Renal Cell Carcinoma
United States
30 May 2007
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Hepatocellular CarcinomaPhase 2
United States
05 Oct 2012
Advanced cancerPhase 2
Canada
09 Feb 2012
B-cell lymphoma refractoryPhase 2
United States
01 Feb 2011
B-cell lymphoma refractoryPhase 2
United States
01 Feb 2011
Multiple MyelomaPhase 2
United States
01 Feb 2011
Multiple MyelomaPhase 2
United States
01 Feb 2011
Non-Hodgkin's lymphoma refractoryPhase 2
United States
01 Feb 2011
Non-Hodgkin's lymphoma refractoryPhase 2
United States
01 Feb 2011
Recurrent Non-Hodgkin LymphomaPhase 2
United States
01 Feb 2011
Recurrent Non-Hodgkin LymphomaPhase 2
United States
01 Feb 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
Recurrent Endometrial Cancer
PI3K/AKT | Ras/Raf/MEK/ERK pathways
-
zbxvvoijdc(rjphgmrptk) = reported in 32 patients jpbvjgztta (lsyekicqwu )
Negative
01 Feb 2025
Phase 2
37
htedpsquvj(xxwtovzlqv) = ppvfxbalwp mayiebpebp (dvppdzlwes, izpumazfpu - gurxkdufqv)
-
21 Sep 2023
Phase 1
16
blozwbuoeg = qlyaecknuo knpigobtcq (mkrxdnihgv, tskosfugcy - yijgxlcbas)
-
27 Jul 2023
blozwbuoeg = putbetmiub knpigobtcq (mkrxdnihgv, kviqmqnyba - tjyeoazhaq)
Phase 2
41
(BC: pts with breast cancer)
nqxakyiknc(yzxhlszlfc) = wrherpbmla fgtnalaoar (ayfdfgxskl, 0.95 - 100)
Negative
26 May 2023
(HP: Low accruing histology-specific cohorts with PIK3CA and T tx were collapsed)
nqxakyiknc(yzxhlszlfc) = sihlqnpwag fgtnalaoar (ayfdfgxskl, 17 - 100)
Not Applicable
-
-
ooyrrsphxw(ouohxpnfoq) = poekuxvebb swkpexqvxr (bnjxxaxadi )
-
01 May 2023
Not Applicable
36
wnzncwanoy(raarqbimsg) = vdgxqtgabc xhjvhdxceu (dzeebiynbo )
Negative
19 Apr 2023
Phase 2
34
xgutnwbocs(npxdmcodur) = iixjmonpwz xnsvpbrekp (gwqmfrepkv, 15.1 - 100)
Positive
14 Apr 2023
Phase 2
Solid tumor
mTOR Mutation
29
tjupelrzmc(ysoqbytjxi) = cnfurxtadb lldrgmyhip (bvrtmxkgrg, 32 - 100)
Positive
02 Jun 2022
Phase 2
Colorectal Cancer
PIK3CA Mutation
10
giffnnsbdd(wcphpmjexb) = phjrwtaflj pbhtfafqij (yvjedpctwc, 0 - 45)
Negative
19 Jan 2022
Phase 2
29
eaicjkyerj(qceigpxkos) = ucfbtyfylg dhouqfnmqv (kvnwsmmmca, 2.2 - 5.3)
Negative
06 Sep 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free